30879-49-3

Usage

Preparation

Preparation by nitration of 3-hydroxyacetophenone,with nitric acid (d = 1.4) in acetic acid, at 70° (31%), (15%)with cupric nitrate in acetic acid–acetic anhydride mixture, between 12° and 15° (20%).

InChI:InChI=1/C8H7NO4/c1-5(10)7-4-6(11)2-3-8(7)9(12)13/h2-4,11H,1H3

Upstream product

• 121-71-1 3-Hydroxyacetophenone 
• 1392043-83-2 bis(3-acetylphenyl) oxalate 

Downstream Products

• 107916-74-5 6,6'-Dinitro-3,3'-dihydroxy-chalkon 
• 418759-59-8 5-O-(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyl)-2-nitroacetophenone 
• 442853-29-4 20α-(3-acetyl-4-nitrophenoxymethyl)-3β-methoxy-5-pregnen 
• 708254-64-2 1-[2-nitro-5-(2-piperidin-1-yl-ethoxy)-phenyl]-ethanone 
• 23042-77-5 1-(2-amino-5-methoxy-phenyl)-ethanone 
• 1159608-45-3 (E)-3-(3-(5-hydroxy-2-nitrophenyl)-3-oxoprop-1-en-1-yl)benzoic acid 
• 1308803-37-3 2-isopropenyl-4-methoxynitrobenzene 
• 42887-67-2 1-(5-methoxy-2-nitrophenyl)ethanone 
• 1224727-68-7 ethyl 4-(3-acetyl-4-nitrophenoxy)butanoate 
• 1392043-84-3 4-(3-acetyl-4-nitrophenoxy)butanoic acid 
• 1331954-73-4 4-(3-(1-hydroxyethyl)-4-nitrophenoxy)butanoic acid 
• 1392043-91-2 4-(3-(1-acryloyloxyethyl)-4-nitrophenoxy)butanoic acid 
• 1438559-19-3 (6-methoxyquinolin-8-yl)(phenyl)methanone 

Relevant academic research and scientific papers

O-NITROBENZYL PHOTOCLEAVABLE BIFUNCTIONAL LINKER

Disclosed herein is an ortho-nitrobenzyl compound, or a stereoisomer or salt thereof, and a composition comprising the same, as well as processes for the preparation of the same. Also disclosed herein is a method of using the ortho-nitrobenzyl compound, o

Design, synthesis and evaluation of 1,3,6-trisubstituted-4-oxo-1,4-dihydroquinoline-2-carboxylic acid derivatives as ETA receptor selective antagonists using FRET assay

The endothelin axis and in particular the two receptor subtypes, ETA and ETB, are under investigation for the treatment of various diseases such as pulmonary arterial hypertension, fibrosis, renal failure and cancer. Previous work in

Photodegradable macromers and hydrogels for live cell encapsulation and release

Hydrogel scaffolds are commonly used as 3D carriers for cells because their properties can be tailored to match natural extracellular matrix. Hydrogels may be used in tissue engineering and regenerative medicine to deliver therapeutic cells to injured or diseased tissue through controlled degradation. Hydrolysis and enzymolysis are the two most common mechanisms employed for hydrogel degradation, but neither allows sequential or staged release of cells. In contrast, photodegradation allows external real-time spatial and temporal control over hydrogel degradation, and allows for staged and sequential release of cells. We synthesized and characterized a series of macromers incorporating photodegradbale ortho-nitrobenzyl (o-NB) groups in the macromer backbone. We formed hydrogels from these macromers via redox polymerization and quantified the apparent rate constants of degradation (kapp) of each via photorheology at 370 nm, 10 mW/cm2. Decreasing the number of aryl ethers on the o-NB group increases kapp, and changing the functionality from primary to seconday at the benzylic site dramatically increases kapp. Human mesenchymal stem cells (hMSCs) survive encapsulation in the hydrogels (90% viability postencapsulation). By exploiting the differences in reactivity of two different o-NB linkers, we quantitatively demonstrate the biased release of one stem cell population (green-fluoroescent protein expressing hMSCs) over another (red-fluorescent protein expressing hMSCs).

Direct exchange of a ketone methyl or aryl group to another aryl group through ciC bond activation assisted by rhodium chelation

Swapped: Commercially available quinolinone derivatives (1 or 2, see scheme) were reacted with arylboronic acids in the presence of a RhI complex to give aryl(quinolin-8-yl)methanone products 3 in medium to good yields. A mechanism that involves the in situ oxidation of RhI to RhIII by O2 in the presence of CuI was proposed. Copyright

Topoisomerase I-mediated antiproliferative activity of 10-substituted and 12-substituted homocamptothecins

Homocamptothecin (hCPT) is an E-ring modified camptothecin (CPT) analogue, which showed pronounced inhibitory activity of topoisomerase I. In search of novel hCPT-type anticancer agents, two series of hCPT derivatives were synthesized and evaluated in vitro against three human tumor cell lines. The results indicated that the 10-substituted hCPT derivatives had a considerably higher cytotoxic activity than the 12-substituted ones. Among the 10-substituted compounds, 8a, 8b, 9b, and 9i showed an equivalent or even more potent activity than the positive control drug topotecan against the lung cancer cell line A-549. Moreover, the hCPT analogues 8a and 8b exhibited a higher topoisomerase I inhibitory activity than CPT at a concentration of 100 μM. Copyright

Synthesis and pharmacological activity of 1,3,6-trisubstituted-4-oxo-1,4- dihydroquinoline-2-carboxylic acids as selective ETA antagonists

A series of 1,3,6-trisubsituted-4-oxo-1,4-dihyroquinoline-2-carboxylic acid analogs (2a-m) were designed and synthesized and their pharmacological activity determined, with the objective to better understand their SAR as potential ETA selective inhibitors. Most of the compounds displayed significant ETA antagonist activity having IC50 for inhibition of binding of the [125I]ET-1 to ETA receptor A antagonism over ETB receptor. Based on the in vitro results, SAR of this series of compounds requires an alkoxy substituent at the 6-position to be a straight and saturated chain up to three carbons long, since substitution of unsaturated and branched alkyloxy groups results in decrease in ETA antagonist activity. In this series, compound 2c (6-O-n-propyl analog) was found to be most potent (IC 50 = 0.11 nM) with ETB/ETA selectivity of 8303.

Phosphate ester derivatives of homocamptothecin: Synthesis, solution stabilities and antitumor activities

Homocamptothecins (hCPTs) represents a new promising class of topoisomerase I inhibitors with enhanced stability and superior antitumor activity. Some phosphodiesters and phosphotriesters homocamptothecin derivatives were designed and synthesized based on our previous synthetic route. The cytotoxicity in vitro on three cancer cell lines and antitumor activity in vivo, and inhibitory properties of topoisomerase I of these derivatives were evaluated. Among them compounds 24e and 24f exhibited higher cytotoxic activity than IRT and the former exhibited the best antitumor activity in vivo and solution stability both at pH 7.4 and pH 3.0.

Synthesis of 1,3,6-trisubstituted-2-carboxyquinol-4-ones as selective ET A antagonists and their use as medicaments

The invention discloses the composition and preparation of various 1,3,6-trisubstituted-2-carboxy-quinol-4-ones of the formula 1 where R is H, alkyl, haloalkyl or hydroxyalkyl, R′ is alkyl, nitro, halogen or NR2′″ where R′″ is alkyl or cycloalk

New benzo[5,6]pyrrolizino[1,2-b]quinolines as cytotoxic agents

An assessment of structure-activity relationships associated with the new benzo[5,6]pyrrolizino[1,2-b]quinoline system displaying potent in vitro cytotoxic activity against the MCF7 cell line is described.

Design, synthesis, photochemical properties and cytotoxic activities of water-Soluble caged L-Leucyl-L-leucine methyl esters that control apoptosis of immune cells

L-Leucyl-L-leucine methyl esters (LeuLeuOMe) is a lysosomotropic agent that induces apoptosis of certain immune cells. Glucose-carrying 2-nitrobenzyl (2-NB) and 2-nitrophenethyl (2-NPE) caged LeuLeuOMe, 1a and b, were synthesized and their photochemical a